These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26789342)

  • 1. EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES.
    Wysham C; Hood RC; Warren ML; Wang T; Morwick TM; Jackson JA
    Endocr Pract; 2016 Jun; 22(6):653-65. PubMed ID: 26789342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL.
    Hood RC; Arakaki RF; Wysham C; Li YG; Settles JA; Jackson JA
    Endocr Pract; 2015 Jul; 21(7):782-93. PubMed ID: 25813411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.
    Kabul S; Hood RC; Duan R; DeLozier AM; Settles J
    Health Qual Life Outcomes; 2016 Sep; 14(1):139. PubMed ID: 27716283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Prestudy Insulin Therapy on Safety and Efficacy of Human Regular U-500 Insulin by Pump or Injection: A Posthoc Analysis.
    Hood RC; Chen Y; Sindelar DK; Ly T; Juneja R; Pollom RD; Ilag L; Wysham C
    Endocr Pract; 2021 Aug; 27(8):783-789. PubMed ID: 33515757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin.
    de la Peña A; Ma X; Reddy S; Ovalle F; Bergenstal RM; Jackson JA
    J Diabetes Sci Technol; 2014 Jul; 8(4):821-9. PubMed ID: 24876428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W; Ji Q; Zhu D; Yang J; Chen L; Liu Z; Yu D; Yan L
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS.
    Mari A; Rosenstock J; Ma X; Li YG; Jackson JA
    Endocr Pract; 2015 Dec; 21(12):1344-52. PubMed ID: 26307903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a Conservative Pharmacist-led U-500R Insulin Management Protocol in the Primary Care Setting.
    Dumont C; Fitzgerald L; Valdez CA
    J Prim Care Community Health; 2020; 11():2150132720973827. PubMed ID: 33218271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns and Outcomes, Before and After Humulin R U-500 Initiation, Among High-Dose Type 2 Diabetes Mellitus Patients in the United States.
    Hood RC; Borra S; Fan L; Pollom RD; Huang A; Chen J
    Endocr Pract; 2021 Aug; 27(8):798-806. PubMed ID: 34089876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating U-500R Randomized Clinical Trial Evidence to the Practice Setting: A Diabetes Educator/Expert Prescriber Team Approach.
    Bergen PM; Kruger DF; Taylor AD; Eid WE; Bhan A; Jackson JA
    Diabetes Educ; 2017 Jun; 43(3):311-323. PubMed ID: 28427304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns and Outcomes Before and After Humulin R U-500 Initiation Among US Patients with Type 2 Diabetes Previously Prescribed ≤ 200 Units/day of U-100 Insulin.
    Chen J; Borra S; Huang A; Fan L; Pollom RD; Hood RC
    Diabetes Ther; 2022 Mar; 13(3):465-479. PubMed ID: 35190970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns and outcomes before and after human regular U-500 insulin initiation via KwikPen® among US veterans with type 2 diabetes mellitus.
    Chen J; Borra S; Fan L; Huang A; Patel D; Juneja R
    J Diabetes Complications; 2021 Oct; 35(10):107995. PubMed ID: 34364779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.
    Bebakar WM; Chaykin L; Hersløv ML; Rasmussen S
    Diabetes Ther; 2017 Feb; 8(1):197-205. PubMed ID: 27853981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Patterns, Adherence, and Persistence Associated With Human Regular U-500 Insulin: A Real-World Evidence Study.
    Chen J; Kao CY; He X; Fan L; Jackson JA; Juneja R
    Diabetes Spectr; 2020 Aug; 33(3):264-272. PubMed ID: 32848348
    [No Abstract]   [Full Text] [Related]  

  • 15. Healthcare costs and adherence associated with human regular U-500 versus high-dose U-100 insulin in patients with diabetes.
    Eby EL; Zagar AJ; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
    Endocr Pract; 2014 Jul; 20(7):663-70. PubMed ID: 24449672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
    Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
    J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study.
    Eby EL; Curtis BH; Gelwicks SC; Hood RC; Idris I; Peters AL; Bergenstal RM; Jackson JA
    BMJ Open Diabetes Res Care; 2015; 3(1):e000074. PubMed ID: 25969741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
    Munshi MN; Gill J; Chao J; Nikonova EV; Patel M
    Endocr Pract; 2018 Feb; 24(2):143-149. PubMed ID: 29106816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.
    Davidson JA; Manghi FP; Yu M; Linetzky B; Landó LF
    Endocr Pract; 2016 Dec; 22(12):1406-1414. PubMed ID: 27540883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. U500 Disposable Patch Insulin Pump: Results and Discussion of a Veterans Affairs Pilot Study.
    Martin C; Perez-Molinar D; Shah M; Billington C
    J Endocr Soc; 2018 Nov; 2(11):1275-1283. PubMed ID: 30402591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.